Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development efforts for RCI and its subsidiaries that are commercializing gene-edited animal models for biomedical and agricultural use, Acceligen and Surrogen. Abrahamsen will also continue to serve on RCI’s Board of Directors.
Before joining RCI, Dr. Abrahamsen held several senior executive roles including serving as Senior Vice President of Research and Development at Cobb-Vantress – a wholly-owned subsidiary of Tyson Foods; Vice President of Research at Hill’s Pet Nutrition for Colgate-Palmolive Co.; and Vice President of Research and Development and Chief Scientific Officer of Pyxis Genomics, Inc. Prior to that, he served as a Professor in the Department of Veterinary Pathobiology and Director of Graduate Studies, Molecular Veterinary Biosciences at University of Minnesota. Dr. Abrahamsen received a Bachelor’s degree in Biochemistry from the University of Minnesota and a PhD in Biochemistry from the University of Washington.
“Mitch’s expertise in the biotechnology industry, combined with skills in strategically developing and commercializing products, will rapidly advance our revenues,” said Ian Friendly, RCI’s Chief Executive Officer. “Mitch will serve as a critical interface between the science and business development teams and provide strategic leadership for all activities relating to sales, product development and customer service to drive business growth as we continue to expand RCI’s gene-editing solutions in the marketplace.”
RCI also announced three internal promotions: Daniel Carlson to Senior Vice President of Science and Technology Development; Tammy Lee Stanoch to Executive Vice President and Chief Administrative Officer; and Justin Zenanko to Senior Vice President of Corporate Development.